Arthralgia with risk of progression to psoriatic arthritis: role of clinical assessments and ultrasound as prognostic factors

Abstract Objectives Referral of patients from dermatology to rheumatology practices due to psoriasis is unnecessary delayed. Many times musculoskeletal symptoms are the first reason for consultation. We aimed to estimate the proportion of ARP-PsA (arthralgia with risk to progression) defined by patients with arthralgia and the presence of psoriasis and/or a family history. Also, identify clinical, laboratory, and imaging prognostic factors of PsA progression within the ARP-PsA group over a one-year follow-up period. Methods Patients were included in a comprehensive arthralgia evaluation program, with the ARP-PsA criteria defined as arthralgia with Pso and/or a family history of Pso, not referred from dermatology. Baseline characteristics were analyzed, and the progression to PsA at one year was assessed. Multivariate analysis identified predictor features for progression. Results Of the 1419 patients, 8.4% met ARP-PsA criteria, and 29% of this subgroup developed PsA at one year. Baseline differences between those who developed PsA and those who did not included family history, Pso duration, pain severity, joint count, and imaging findings (X-ray and ultrasound). Multivariate analysis revealed the predictive significance of a combination of Pso plus family history of psoriasis disease, synovitis by Power Doppler ultrasound, ultrasound enthesopathy findings, and low tender joint count. Conclusion The frequency of patients ARP-PsA was 8.4%, of whom 29% developed PsA at 1-year. The main predictor variables for this progression were identified.